180 related articles for article (PubMed ID: 29692265)
21. Elevated SP/NK-1R in esophageal carcinoma promotes esophageal carcinoma cell proliferation and migration.
Dong J; Feng F; Xu G; Zhang H; Hong L; Yang J
Gene; 2015 Apr; 560(2):205-10. PubMed ID: 25659767
[TBL] [Abstract][Full Text] [Related]
22. A Novel Mechanism of Endoplasmic Reticulum Stress- and c-Myc-Degradation-Mediated Therapeutic Benefits of Antineurokinin-1 Receptor Drugs in Colorectal Cancer.
Shi Y; Wang X; Meng Y; Ma J; Zhang Q; Shao G; Wang L; Cheng X; Hong X; Wang Y; Yan Z; Cao Y; Kang J; Fu C
Adv Sci (Weinh); 2021 Nov; 8(21):e2101936. PubMed ID: 34605226
[TBL] [Abstract][Full Text] [Related]
23. The NK-1 receptor antagonist L-732,138 induces apoptosis in human gastrointestinal cancer cell lines.
Muñoz M; Rosso M; Coveñas R
Pharmacol Rep; 2017 Aug; 69(4):696-701. PubMed ID: 28550801
[TBL] [Abstract][Full Text] [Related]
24. A new frontier in the treatment of cancer: NK-1 receptor antagonists.
Muñoz M; Rosso M; Coveñas R
Curr Med Chem; 2010; 17(6):504-16. PubMed ID: 20015033
[TBL] [Abstract][Full Text] [Related]
25. NK-1 receptor antagonists: a new paradigm in pharmacological therapy.
Muñoz M; Coveñas R
Curr Med Chem; 2011; 18(12):1820-31. PubMed ID: 21466470
[TBL] [Abstract][Full Text] [Related]
26. The NK-1 receptor antagonist aprepitant as a broad spectrum antitumor drug.
Muñoz M; Rosso M
Invest New Drugs; 2010 Apr; 28(2):187-93. PubMed ID: 19148578
[TBL] [Abstract][Full Text] [Related]
27. NK-1 receptor antagonists induce apoptosis and counteract substance P-related mitogenesis in human laryngeal cancer cell line HEp-2.
Muñoz M; Rosso M; Aguilar FJ; González-Moles MA; Redondo M; Esteban F
Invest New Drugs; 2008 Apr; 26(2):111-8. PubMed ID: 17906845
[TBL] [Abstract][Full Text] [Related]
28. Neurokinin-1 Receptor Antagonists against Hepatoblastoma.
Muñoz M; Rosso M; Coveñas R
Cancers (Basel); 2019 Aug; 11(9):. PubMed ID: 31466222
[TBL] [Abstract][Full Text] [Related]
29. Human acute myeloid leukemia cells express Neurokinin-1 receptor, which is involved in the antileukemic effect of Neurokinin-1 receptor antagonists.
Molinos-Quintana A; Trujillo-Hacha P; Piruat JI; Bejarano-García JA; García-Guerrero E; Pérez-Simón JA; Muñoz M
Invest New Drugs; 2019 Feb; 37(1):17-26. PubMed ID: 29721755
[TBL] [Abstract][Full Text] [Related]
30. Advances in the research and application of neurokinin-1 receptor antagonists.
Hong X; Ma J; Zheng S; Zhao G; Fu C
J Zhejiang Univ Sci B; 2024 Feb; 25(2):91-105. PubMed ID: 38303494
[TBL] [Abstract][Full Text] [Related]
31. NK-1 as a melanoma target.
Muñoz M; Bernabeu-Wittel J; Coveñas R
Expert Opin Ther Targets; 2011 Jul; 15(7):889-97. PubMed ID: 21592000
[TBL] [Abstract][Full Text] [Related]
32. Uveal melanoma expresses NK-1 receptors and cyclosporin A induces apoptosis in human melanoma cell lines overexpressing the NK-1 receptor.
González-Ortega A; Sánchez-Vaderrábanos E; Ramiro-Fuentes S; Salinas-Martín MV; Carranza A; Coveñas R; Muñoz M
Peptides; 2014 May; 55():1-12. PubMed ID: 24548567
[TBL] [Abstract][Full Text] [Related]
33. Neurokinin-1 Receptor (NK-1R) Antagonists: Potential Targets in the Treatment of Glioblastoma Multiforme.
Afshari AR; Motamed-Sanaye A; Sabri H; Soltani A; Karkon-Shayan S; Radvar S; Javid H; Mollazadeh H; Sathyapalan T; Sahebkar A
Curr Med Chem; 2021; 28(24):4877-4892. PubMed ID: 33441062
[TBL] [Abstract][Full Text] [Related]
34. Antagonism of NK-1R using aprepitant suppresses inflammatory response in rheumatoid arthritis fibroblast-like synoviocytes.
Liu X; Zhu Y; Zheng W; Qian T; Wang H; Hou X
Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):1628-1634. PubMed ID: 31010320
[TBL] [Abstract][Full Text] [Related]
35. The neurokinin 1 receptor regulates peritoneal fibrinolytic activity and postoperative adhesion formation.
Cassidy MR; Sheldon HK; Gainsbury ML; Gillespie E; Kosaka H; Heydrick S; Stucchi AF
J Surg Res; 2014 Sep; 191(1):12-8. PubMed ID: 24836694
[TBL] [Abstract][Full Text] [Related]
36. Characteristics of substance P transport across the blood-brain barrier.
Chappa AK; Audus KL; Lunte SM
Pharm Res; 2006 Jun; 23(6):1201-8. PubMed ID: 16729222
[TBL] [Abstract][Full Text] [Related]
37. The NK-1 receptor is expressed in human primary gastric and colon adenocarcinomas and is involved in the antitumor action of L-733,060 and the mitogenic action of substance P on human gastrointestinal cancer cell lines.
Rosso M; Robles-Frías MJ; Coveñas R; Salinas-Martín MV; Muñoz M
Tumour Biol; 2008; 29(4):245-54. PubMed ID: 18781096
[TBL] [Abstract][Full Text] [Related]
38. Role of NK-1 and NK-2 tachykinin receptor antagonism on the growth of human breast carcinoma cell line MDA-MB-231.
Bigioni M; Benzo A; Irrissuto C; Maggi CA; Goso C
Anticancer Drugs; 2005 Nov; 16(10):1083-9. PubMed ID: 16222150
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of the antileukemic effects of neurokinin-1 receptor antagonists, aprepitant, and L-733,060, in chronic and acute myeloid leukemic cells.
Dikmen M; Gökhaner G; Cantürk Z
Anticancer Drugs; 2019 Aug; 30(7):e0769. PubMed ID: 31306152
[TBL] [Abstract][Full Text] [Related]
40. The Neurokinin-1 Receptor Is a Target in Pediatric Rhabdoid Tumors.
Kolorz J; Demir S; Gottschlich A; Beirith I; Ilmer M; Lüthy D; Walz C; Dorostkar MM; Magg T; Hauck F; von Schweinitz D; Kobold S; Kappler R; Berger M
Curr Oncol; 2021 Dec; 29(1):94-110. PubMed ID: 35049682
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
